Scancell (SCLP.L)

Executive Summary

Scancell is a clinical-stage biotechnology company developing novel active immunotherapies for cancer, leveraging its proprietary Immunobody® and Moditope® platforms to create off-the-shelf treatments that stimulate durable, tumor-specific immune responses. The company's lead program, SCIB1, targets advanced melanoma and is currently in Phase 3 clinical trials. Scancell's Immunobody platform generates antibodies that directly kill tumor cells and activate T-cells, while the Moditope platform induces potent CD4+ T-cell responses against tumor-specific peptides. These platforms offer potential advantages in treating hard-to-treat solid tumors, addressing significant unmet medical needs. With a market cap of ~$157 million, Scancell represents an early-stage investment opportunity in the immuno-oncology space, pending clinical data readouts and regulatory milestones. Scancell's near-term value drivers include the completion of its Phase 3 trial for SCIB1 in advanced melanoma, which could lead to a marketing authorization application in the UK and Europe. Additionally, the company is advancing preclinical and early-stage programs targeting other solid tumors, potentially expanding its pipeline. The company's financial position and partnerships will be critical for funding development and commercialization. As a Phase 3 company with a novel platform, Scancell offers significant upside potential but also carries inherent clinical and regulatory risks typical of biotech investments.

Upcoming Catalysts (preview)

• H2 2026Phase 3 SCIB1 Data Readout in Advanced Melanoma50% success
• Q1 2027Regulatory Submission for SCIB1 in UK/Europe40% success
• TBDPartnership or Licensing Deal for Moditope Platform30% success